Mabion S.A.
Aleksandra Stasiak is a highly skilled professional with extensive experience in risk management and biotechnology. Currently serving as a Senior Registration Documentation Specialist and Senior Risk Management Specialist at Mabion S.A. since October 2014, Aleksandra leads risk management for the technology transfer of Novavax and has contributed significantly to monoclonal antibody production processes. Previous roles include process engineer in the Quality Assurance Department and manufacturing, as well as a specialist in risk management. Aleksandra's educational background includes a Master's degree in Biotechnology from Lodz University of Technology, along with postgraduate studies in project management at SGH Warsaw School of Economics. Additionally, Aleksandra has completed internships at notable institutions, reinforcing expertise in bioimmunology and GMP practices.
Mabion S.A.
2 followers
Mabion S.A. (WSE: MAB) is a Polish biopharmaceutical company founded in 2007, which is undergoing a transformation into a fully integrated contract development and manufacturing organisation (CDMO) providing a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early stage discovery to commercial manufacturing). Mabion's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances "Drug Substance" and Finished Products "Drug Product"), the development of analytical tools (for structural, functional, physicochemical characterisation), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The company signed a record contract with Novavax in October 2021 for the commercial production of antigen for the COVID-19 vaccine, which it has since steadily expanded through further services under the Statement of Work (SOW) and annexes signed, adding, among other things, another vaccine product based on the Omicron variant. In line with the Strategy announced in April 2023, the Company's objective is to establish itself as a recognisable player in the global contract manufacturing and contract drug development market and to complete the full transformation of Mabion into an integrated biologics CDMO company. Mabion is a public Company, listed on the Warsaw Stock Exchange. For more information about the Company, visit www.mabion.eu.